Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab

Immunotherapy. 2016 Jun;8(6):687-92. doi: 10.2217/imt-2015-0025. Epub 2016 Apr 26.

Abstract

Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis and was subsequently treated with the anti-programmed cell death 1 protein (PD-1) antibody pembrolizumab. He has been on treatment with pembrolizumab for more than 20 months with no major toxicities and has achieved an objective partial response, which is ongoing.

Keywords: anti-CTLA-4; anti-PD-1; immune-related adverse event; melanoma.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • CTLA-4 Antigen / immunology
  • Colitis / drug therapy*
  • Colitis / etiology
  • Drug-Related Side Effects and Adverse Reactions / drug therapy*
  • Humans
  • Ipilimumab
  • Male
  • Melanoma / complications
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Metastasis
  • Programmed Cell Death 1 Receptor / immunology
  • Proto-Oncogene Proteins B-raf / genetics
  • Quality of Life
  • Withholding Treatment

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • Ipilimumab
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • pembrolizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf